Jaffer Ajani
Professor, GI Medical Oncology · University of Texas M D Anderson Cancer Center
Credentials: · · · ·
History
1974–1977- 1972–1974
- 1967–1971
Doctor of Medicine
Research
New England Journal of Medicine · 2001 · 2,702 citations
The Lancet · 2021 · Last of 29 authors · 2,551 citations
The Lancet Oncology · 2014 · 1,973 citations
153 papers · 1 as a fellow
142 papers
125 papers · 13 as a fellow
94 papers · 1 as a fellow
91 papers
89 papers · 66 as a resident
89 papers · 1 as a resident
82 papers
Grants
- 2022–2027
Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
National Cancer Institute · R01
PI · $4.6M · Wake Forest University Health Sciences
- 2013–2019
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE Junction
National Cancer Institute · R01
Contact PI · $1.4M · University of Tx Md Anderson Can Ctr
- 2010–2016
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
National Cancer Institute · R01
Contact PI · $1.5M · University of Tx Md Anderson Can Ctr
- 2009–2012
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer
National Cancer Institute · R21
Contact PI · $366.6K · University of Tx Md Anderson Can Ctr
Clinical trials
- 2020–2026
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
- 2019–2026
Trial of DFP-14927 in Advanced Solid Tumors
Principal investigator · Recruiting · Phase 1
Delta-Fly Pharma, Inc.
- 2018–2023
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
Principal investigator · Completed · Early phase 1
M.D. Anderson Cancer Center
- 2017–2022
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center